Imatics宣布对反应率为54%的高级黑瘤进行ACTENGINE IMA203;计划在2024年12月前进行第三阶段试验。 Immatics announces ACTengine® IMA203 for advanced melanoma with a 54% response rate; plans Phase 3 trial by December 2024.

Immatics已经公布了其ACTENGine IMA203第1b阶段的最新数据,针对28名患有高级黑素瘤的病人中的PRAME。 Immatics has released updated Phase 1b data for its ACTengine® IMA203, targeting PRAME in 28 patients with advanced melanoma. 治疗表明,经确认的客观回应率为54%,中位无累进生存(PFS)为6个月。 The treatment shows a confirmed objective response rate of 54%, with a median progression-free survival (PFS) of 6 months. 该公司计划在2024年12月之前启动第三期试验"SUPRAME",招募360名患者,以评估中位PFS作为潜在的全面批准的主要终点. The company plans to initiate a Phase 3 trial, "SUPRAME," by December 2024, enrolling 360 patients to assess median PFS as the primary endpoint for potential full approval.